Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of etrasimod in moderately to severely active ulcerative colitis
2018-003986-33Phase 3Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrasimod with Placebo (2 arms). Primary endpoints: Clinical remission at 12 weeks and Clinical remission at 52 weeks. Started May 2019; status: completed.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-003986-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003986-33.